Research Roundup


smart light bulb on orange background

Debbie Rigby rounds up the latest in research news

Physical functioning and mindfulness skills training in chronic pain

The importance of improved physical function as a primary outcome in the treatment of chronic pain is widely accepted. This systematic review evaluated published reports of original randomized controlled trials on mindfulness skills training; and reports inconclusive evidence for efficacy for improving physical functioning. Patients are encouraged to use mindfulness in order to participate fully in the present moment, which may involve mindful participation in physical activities.

Journal of Pain Research 2019;12:179–189.

 

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes

A systematic review and meta-analysis of 3 trials shows SGLT2 inhibitors reduce major adverse cardiovascular events by 11%, with benefit only seen in patients with atherosclerotic cardiovascular disease. SGLT2i also reduce the risk of cardiovascular death or hospitalisation for heart failure by 23%; and reduces the risk of progression of renal disease by 45%, with a similar benefit in those with and without atherosclerotic cardiovascular disease.

Lancet 2019;393:31-39.

 

Stability of repackaged dabigatran etexilate capsules in dose administration aids

This study has clearly demonstrated that if repackaging of Pradaxa capsules is required, storage under refrigerated conditions ensures quality for 28 days. Storage at ambient conditions for 14 and 28 days resulted in a percentage drug remaining of 92.5% and 71.6%, respectively.

European Journal of Hospital Pharmacy 2018;25:e93-e97.

 

Deprescribing Benzodiazepine Receptor Agonists for Insomnia in Adults

Benzodiazepine receptor agonists are beneficial for short-term improvement in sleep onset latency and duration, they also have associated harms, including problems with dependence. A slow taper of BZRAs is recommended in patients 18 to 64 years of age who use these most days of the week for more than four weeks. Patients 65 years and older taking a BZRA for any duration should be recommended to taper off slowly. A slow taper with a 25% dose reduction every two weeks and medication-free days at the end of the taper is suggested.

Am Fam Physician. 2019;99(1):57-58.

Editorial

 

Previous Hitting the target
Next Doctors ‘declare war’ on the Pharmacy Guild

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.